These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 12061944)

  • 81. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study.
    Fang T; Al Khleifat A; Meurgey JH; Jones A; Leigh PN; Bensimon G; Al-Chalabi A
    Lancet Neurol; 2018 May; 17(5):416-422. PubMed ID: 29525492
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.
    Lacomblez L; Bensimon G; Leigh PN; Guillet P; Meininger V
    Lancet; 1996 May; 347(9013):1425-31. PubMed ID: 8676624
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Survival prediction in amyotrophic lateral sclerosis.
    Jablecki CK; Berry C; Leach J
    Muscle Nerve; 1989 Oct; 12(10):833-41. PubMed ID: 2608080
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Epidemiological and clinical features of amyotrophic lateral sclerosis in a Tunisian cohort.
    Kacem I; Sghaier I; Bougatef S; Nasri A; Gargouri A; Ajroud-Driss S; Gouider R
    Amyotroph Lateral Scler Frontotemporal Degener; 2020 Feb; 21(1-2):131-139. PubMed ID: 31858811
    [No Abstract]   [Full Text] [Related]  

  • 85. Clinical features and prognosis of amyotrophic lateral sclerosis in Africa: the TROPALS study.
    Luna J; Diagana M; Ait Aissa L; Tazir M; Ali Pacha L; Kacem I; Gouider R; Henning F; Basse A; Cisse O; Balogou AAK; Kombate D; Agbetou M; Houinato D; Millogo A; Agba T; Belo M; Penoty M; Raymondeau-Moustafa M; Hamidou B; Couratier P; Preux PM; Marin B;
    J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):20-29. PubMed ID: 30242088
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [The advance in the research and therapeutic trials of amyotrophic lateral sclerosis].
    Moriwaka F; Tashiro K
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1258-60. PubMed ID: 11464472
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Glutamate antagonist].
    Shindo M
    No To Shinkei; 1998 Jul; 50(7):597-605. PubMed ID: 9739517
    [No Abstract]   [Full Text] [Related]  

  • 88. Predicting survival of patients with amyotrophic lateral sclerosis at presentation: a 15-year experience.
    Gordon PH; Salachas F; Lacomblez L; Le Forestier N; Pradat PF; Bruneteau G; Elbaz A; Meininger V
    Neurodegener Dis; 2013; 12(2):81-90. PubMed ID: 22922503
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan.
    Lee CT; Chiu YW; Wang KC; Hwang CS; Lin KH; Lee IT; Tsai CP
    J Epidemiol; 2013; 23(1):35-40. PubMed ID: 23117224
    [TBL] [Abstract][Full Text] [Related]  

  • 90. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole.
    Riviere M; Meininger V; Zeisser P; Munsat T
    Arch Neurol; 1998 Apr; 55(4):526-8. PubMed ID: 9561981
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.
    Bensimon G; Lacomblez L; Meininger V
    N Engl J Med; 1994 Mar; 330(9):585-91. PubMed ID: 8302340
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Amyotrophic Lateral Sclerosis Survival Score (ALS-SS): A simple scoring system for early prediction of patient survival.
    Lunetta C; Lizio A; Melazzini MG; Maestri E; Sansone VA
    Amyotroph Lateral Scler Frontotemporal Degener; 2015; 17(1-2):93-100. PubMed ID: 26470943
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Clinical, demographic and prognostic features of sporadic amyotrophic lateral sclerosis in Northern Turkey.
    Aksoy D; Cevik B; Solmaz V; Kurt SG
    Int J Neurosci; 2014 Jan; 124(1):68-73. PubMed ID: 23837674
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Factors Predicting Survival in ALS Patients--Data from a Population-Based Registry in Rhineland-Palatinate, Germany.
    Wolf J; Safer A; Wöhrle JC; Palm F; Nix WA; Maschke M; Grau AJ
    Neuroepidemiology; 2015; 44(3):149-55. PubMed ID: 25895515
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis.
    Su XW; Simmons Z; Mitchell RM; Kong L; Stephens HE; Connor JR
    JAMA Neurol; 2013 Dec; 70(12):1505-11. PubMed ID: 24145899
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [Pharmacotherapy of amyotrophic lateral sclerosis].
    Jokelainen M
    Duodecim; 1997; 113(6):513-6. PubMed ID: 11370073
    [No Abstract]   [Full Text] [Related]  

  • 97. Birth cohort effects in neurological diseases: amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis.
    Ajdacic-Gross V; Schmid M; Tschopp A; Gutzwiller F
    Neuroepidemiology; 2012; 38(1):56-63. PubMed ID: 22236983
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Rate of disease progression: a prognostic biomarker in ALS.
    Labra J; Menon P; Byth K; Morrison S; Vucic S
    J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):628-32. PubMed ID: 26152368
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Riluzole and other prognostic factors in ALS: a population-based registry study in Italy.
    Mandrioli J; Malerba SA; Beghi E; Fini N; Fasano A; Zucchi E; De Pasqua S; Guidi C; Terlizzi E; Sette E; Ravasio A; Casmiro M; Salvi F; Liguori R; Zinno L; Handouk Y; Rizzi R; Borghi A; Rinaldi R; Medici D; Santangelo M; Granieri E; Mussuto V; Aiello M; Ferro S; Vinceti M;
    J Neurol; 2018 Apr; 265(4):817-827. PubMed ID: 29404735
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Riluzole in amyotrophic lateral sclerosis.
    Murphy JR
    N Engl J Med; 1994 Jul; 331(4):273; author reply 273-4. PubMed ID: 8015580
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.